As the drug development landscape rapidly evolves, artificial intelligence (AI) is emerging as a transformative force, fundamentally reshaping processes and enhancing efficiencies. This webinar delves ...

Oruka Therapeutics, Inc. announced progress in its clinical programs with ORKA-001 and ORKA-002, targeting chronic skin diseases like psoriasis. The company completed dosing in a Phase 1 trial for ...

SAN DIEGO, CA / ACCESS Newswire / January 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or ...

YD BioMed expects to advance two lead ophthalmology programs utilizing its LSC Exosome platform, each supported by targeted regulatory and clinical milestones, which the timing of these milestones ...

Aragen's new cell line development and early manufacturing platform, CHOMax, can cut timelines to approximately 10 months.

BostonGene, the developer of an AI foundation model for tumor and immune biology, has entered a strategic collaboration with ...

Designed specifically for emerging biotechs, the Early Phase Center of Excellence brings together Avance Clinical’s scientific, regulatory, and operational experts to streamline first-in-human and ...

The biopharmaceutical company now anticipates topline data from its ZEPHYR trial for schizophrenia treatment ML-007C-MA in the third quarter of 2026. The study, which will enroll 300 hospitalized ...

Site augmentation emerges as a dynamic response to the growing complexity and volume of clinical trials, and the challenge of limited resources at clinical research sites. This support model, which is ...

Rapid enrollment in Phase 2 portions of the ARROS-1 and ALKOVE-1 clinical trials; Pivotal data from both ROS1 and ALK programs now anticipated in 2025 Initiation of ALKAZAR Phase 3 randomized, ...

The coronavirus pandemic prompted the speedy development of lifesaving Covid-19 vaccines, showcasing the pharmaceutical industry’s ability to deliver groundbreaking scientific innovations to the ...

Recently, VivaVision Biotech (VivaVision), a late clinical-stage, privately-held biotech company focused on developing innovative ophthalmic drugs, announced that it has received the written meeting ...